{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:25:06Z","timestamp":1767165906495,"version":"build-2238731810"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":220,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGJ20H20001"],"award-info":[{"award-number":["LGJ20H20001"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Contrast Media &amp; Molecular Imaging"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>\n                    Heart failure is a group of syndromes caused by various cardiac structural or functional disorders leading to impaired ventricular filling and (or) ejection capacity. Because of decreased ventricular systolic function and impaired ejection function, the amount of cardiac output cannot meet the body\u2019s metabolic needs; organ and tissue blood perfusion is insufficient; at the same time, pulmonary circulation and (or) systemic circulation congestion; the clinical manifestations are mainly dyspnea and weakness but restricted physical activity and edema. Treatment of the disease should include preventing and delaying the onset of wails, relieving symptoms of clinical wails, improving its long\u2010term prognosis, and reducing mortality. The aim of the study is to observe the efficacy and safety of Entresto in the treatment of left ventricular ejection fraction heart failure (HFpEF). Seventy\u2010eight patients with HFpEF treated in our hospital from October 2017 to April 2018 were randomized into a treatment group (Entresto 50\u2009mg\u2009+\u2009basic treatment,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939) and a control group (basic treatment,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939). The course of treatment was ten weeks. The levels of brain natriuretic peptide (BNP) and echocardiographic indicators (LVMI, LVEF, LVEDD, LVESD, E\/E\u2032 Ratio, E\/A ratio, DT), 6\u2010minute walking test (6MWD), and Minnesota Quality of Life Scale (MLHFQ) were analyzed before and after treatment. LVMI, LVEF, LVEDD, LVESD, E\/E\u2032 ratio, E\/A ratio, DT, and BNP were all significantly improved in the Entresto group after treatment. In the control group, except for LVEDD, LVESD, the E\/A ratio, and BNP, other indicators were significantly improved after treatment (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). Posttreatment, both groups had significantly improved 6MWD and MLHFQ scores (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). Differences in these parameters between the two groups were statistically significant (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). After treatment, the levels of NE, AngII, ALD, and MMP\u20109 in the two groups were decreased (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05), with the lower lever in the treatment group (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). The effective rate was 76.92% in the control group and 94.87% in the Entresto group, and this rate difference was statistically significant (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). The number of patients re\u2010hospitalized due to cardiovascular events was 2 (the Entresto group) vs. 7 (the control group) cases; worsening of heart failure was observed in 1 patient (the Entresto group) vs. 6 (the control group), and the difference between the two groups was statistically significant (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). However, the incidence of adverse reactions between the two groups was not statistically significant. Entresto can significantly improve left ventricular diastolic function in heart failure patients with preserved left ventricular ejection fraction and improve quality of life. This treatment is safe and effective and worthy of clinical application. This trail is registered with\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/ChiCTR2000031486\">ChiCTR2000031486<\/jats:ext-link>\n                    . This trial was approved by the Chinese Clinical Trial Registry (clinical trial number: ChiCTR2000031486). The registration number of this study is 2022\u2010R008.\n                  <\/jats:p>","DOI":"10.1155\/2022\/4164089","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:50:11Z","timestamp":1660071011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["[Retracted] Clinical Study of Heart Failure with Left Ventricular Ejection Fraction Regimen Treated with Entresto"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-9849","authenticated-orcid":false,"given":"Mingjun","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-4506","authenticated-orcid":false,"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-3878","authenticated-orcid":false,"given":"Binhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-0452","authenticated-orcid":false,"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2791-6831","authenticated-orcid":false,"given":"Huimin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"e_1_2_9_1_2","first-page":"66","article-title":"Analysis of the efficacy of atorvastatin calcium in the treatment of coronary heart disease and heart failure and its effect on cardiac function","volume":"9","author":"Yang Y. Q.","year":"2018","journal-title":"Chinese Community Doctors"},{"key":"e_1_2_9_2_2","first-page":"20","article-title":"Progress research on diastolic heart failure","volume":"14","author":"Zhou Q.","year":"2015","journal-title":"Chinese Journal of integrative medicine on Cardio-Cerebrovascular Disease"},{"key":"e_1_2_9_3_2","first-page":"3","article-title":"Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population","volume":"31","author":"Gu D. F.","year":"2003","journal-title":"Chinese Journal of Cardiology"},{"key":"e_1_2_9_4_2","first-page":"790","article-title":"[Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients]","volume":"29","author":"H\u00e9bert M.","year":"2000","journal-title":"Presse Medicale"},{"key":"e_1_2_9_5_2","article-title":"Or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"350","author":"Valsartan C.","year":"2004","journal-title":"Erratum Appears in N Engl J Med"},{"key":"e_1_2_9_6_2","first-page":"98","article-title":"Chinese heart failure association of Chinese medical doctor association, editorial board of Chinese journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2014","volume":"42","year":"2014","journal-title":"Chinese Journal of Cardiology"},{"key":"e_1_2_9_7_2","first-page":"51","article-title":"2013ACCF\/AHAInterpretation of heart failure management guidelines","volume":"62","author":"Chen Y.","year":"2013","journal-title":"Chinese Journal of Practical Internal Medicine"},{"key":"e_1_2_9_8_2","first-page":"21","article-title":"New progress in heart failure with preserved ejection fraction","volume":"38","author":"Zuo Y. X.","year":"2017","journal-title":"Advances in Cardiovascular Disease"},{"key":"e_1_2_9_9_2","first-page":"951","article-title":"Advances in drug therapy in patients with heart failure with preserved ejection fraction","volume":"16","author":"Guo Y. K.","year":"2017","journal-title":"Chinese Journal of Difficult and Complicated Cases"},{"key":"e_1_2_9_10_2","first-page":"107","article-title":"Clinical features of heart failure with preserved ejection fraction","volume":"37","author":"Li Y. P.","year":"2016","journal-title":"Journal of Kunming Medical University"},{"key":"e_1_2_9_11_2","first-page":"125","article-title":"Clinical study of Shenling Yangxin granule in the treatment of heart failure with preserved ejection fraction","volume":"1","author":"Tian X. T.","year":"2018","journal-title":"Journal of Shandong University of Traditional Chinese Medicine"},{"key":"e_1_2_9_12_2","first-page":"92","article-title":"Advances in research on the mechanism of heart failure with ejection fraction preservation","volume":"23","author":"Liu N. N.","year":"2014","journal-title":"Chinese Journal of Cardiovascular Rehabilitation Medicine"},{"key":"e_1_2_9_13_2","first-page":"766","article-title":"Research progress of heart failure with preserved left ventricular ejection fraction","volume":"18","author":"Wang J. Y.","year":"2016","journal-title":"Chinese Journal of Geriatric Heart Brain and Vessel Diseases"},{"key":"e_1_2_9_14_2","first-page":"720","article-title":"Research progress in diagnosis and treatment of heart failure with preserved left ventricular ejection fraction","volume":"6","author":"Wan X. S.","year":"2015","journal-title":"Chinese Heart Journal"},{"key":"e_1_2_9_15_2","first-page":"706","article-title":"Heart failure with preserved left ventricular ejection fraction","volume":"5","author":"Hu D. Y.","year":"2015","journal-title":"Chinese Journal of Evidence-based Cardiovascular Medicine"},{"key":"e_1_2_9_16_2","first-page":"198","article-title":"Pharmacokinetic and pharmacodynamic characteristics of sacubitril and valsartan","volume":"33","author":"Liu Y.","year":"2018","journal-title":"Chinese Circulation Journal"},{"key":"e_1_2_9_17_2","first-page":"851","article-title":"Research progress of dual-acting angiotensin receptor-enkephalinase inhibitor sacubitril\/valsartan","volume":"12","author":"Zhang H. L.","year":"2017","journal-title":"World Clinical Drugs"},{"key":"e_1_2_9_18_2","first-page":"2280","article-title":"PARADIGM-HF test and its important clinical significance","volume":"9","author":"Liu J. L.","year":"2015","journal-title":"Chinese Journal for Clinicians"},{"key":"e_1_2_9_19_2","first-page":"203","article-title":"Interpretation of PARADIGM-HF study results","volume":"33","author":"Cui X. T.","year":"2018","journal-title":"Chinese Circulation Journal"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1927006"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80083-w"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.033"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9102727"},{"key":"e_1_2_9_26_2","first-page":"281","article-title":"Relationship between ejection fraction and the efficacy and prognosis of low-dose spironolactone in the treatment of ejection fraction-preserving heart failure","volume":"23","author":"Kang R.","year":"2020","journal-title":"Chinese General Practice"}],"updated-by":[{"DOI":"10.1155\/2023\/9803791","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"record-id":"55262"},{"DOI":"10.1155\/2023\/9803791","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000}}],"container-title":["Contrast Media &amp; Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmi\/2022\/4164089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmi\/2022\/4164089.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/4164089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:04:19Z","timestamp":1721790259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/4164089"}},"subtitle":[],"editor":[{"given":"Mohammad Farukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/4164089"],"URL":"https:\/\/doi.org\/10.1155\/2022\/4164089","archive":["Portico"],"relation":{},"ISSN":["1555-4309","1555-4317"],"issn-type":[{"value":"1555-4309","type":"print"},{"value":"1555-4317","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2022-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"4164089"}}